{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:54:22Z","timestamp":1766516062315},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,2]]},"DOI":"10.7759\/cureus.46392","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:47:00Z","timestamp":1696315620000},"source":"Crossref","is-referenced-by-count":1,"title":["Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Akihiro","family":"Tsukaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1839-4303","article-title":"Severe immune checkpoint inhibitor-associated gastritis: a case series and literature review","volume":"10","author":"Sugiyama Y","year":"2022","unstructured":"Sugiyama Y, Tanabe H, Matsuya T, et al.. Severe immune checkpoint inhibitor-associated gastritis: a case series and literature review. Endosc Int Open. 2022, 10:E982-9. 10.1055\/a-1839-4303","journal-title":"Endosc Int Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami H","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al.. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017, 35:529-36. 10.1007\/s10637-017-0453-0","journal-title":"Invest New Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2330-18","article-title":"Successful treatment of nivolumab-related cholangitis with prednisolone: A case report and review of the literature","volume":"58","author":"Sawada K","year":"2019","unstructured":"Sawada K, Shonaka T, Nishikawa Y, et al.. Successful treatment of nivolumab-related cholangitis with prednisolone: A case report and review of the literature. Intern Med. 2019, 58:1747-52. 10.2169\/internalmedicine.2330-18","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01136-z","article-title":"Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis","volume":"39","author":"Takinami M","year":"2021","unstructured":"Takinami M, Ono A, Kawabata T, et al.. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021, 39:1716-23. 10.1007\/s10637-021-01136-z","journal-title":"Invest New Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0077","article-title":"Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma","volume":"11","author":"C\u01celug\u01cereanu A","year":"2019","unstructured":"C\u01celug\u01cereanu A, Rompteaux P, Bohelay G, et al.. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy. 2019, 11:1005-13. 10.2217\/imt-2019-0077","journal-title":"Immunotherapy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-020-01218-0","article-title":"A rare case of immunotherapy-induced cholangitis and gastritis","volume":"13","author":"Fujii M","year":"2020","unstructured":"Fujii M, Ozato T, Mizukawa S, et al.. A rare case of immunotherapy-induced cholangitis and gastritis. Clin J Gastroenterol. 2020, 13:1083-90. 10.1007\/s12328-020-01218-0","journal-title":"Clin J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya Y","year":"2019","unstructured":"Koya Y, Shibata M, Shinohara N, et al.. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work. Hepatol Res. 2019, 49:950-6. 10.1111\/hepr.13329","journal-title":"Hepatol Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1055\/a-0640-2392","article-title":"Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer","volume":"50","author":"Kuraoka N","year":"2018","unstructured":"Kuraoka N, Hara K, Terai S, Yatabe Y, Horio Y. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. Endoscopy. 2018, 50:E259-61. 10.1055\/a-0640-2392","journal-title":"Endoscopy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211028570","article-title":"Immunotherapy-related gastritis: two case reports and literature review","volume":"15","author":"Woodford R","year":"2021","unstructured":"Woodford R, Briscoe K, Tustin R, Jain A. Immunotherapy-related gastritis: two case reports and literature review. Clin Med Insights Oncol. 2021, 15:11795549211028570. 10.1177\/11795549211028570","journal-title":"Clin Med Insights Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama T","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al.. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020, 26:353-65. 10.3748\/wjg.v26.i3.353","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla M","year":"2020","unstructured":"Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 2020, 76:531-9. 10.1111\/his.14029","journal-title":"Histopathology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2019.1923","article-title":"Nivolumab-induced cholangitis in patients with non-small cell lung cancer: case series and a review of literature","volume":"11","author":"Izumi H","year":"2019","unstructured":"Izumi H, Kodani M, Kurai J, et al.. Nivolumab-induced cholangitis in patients with non-small cell lung cancer: case series and a review of literature. Mol Clin Oncol. 2019, 11:439-46. 10.3892\/mco.2019.1923","journal-title":"Mol Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.560","article-title":"Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient","volume":"8","author":"Matsumoto S","year":"2020","unstructured":"Matsumoto S, Watanabe K, Kobayashi N, Irie K, Yamanaka S, Kaneko T. Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. Respirol Case Rep. 2020, 8:e00560. 10.1002\/rcr2.560","journal-title":"Respirol Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025774","article-title":"A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy","volume":"100","author":"Hirasawa Y","year":"2021","unstructured":"Hirasawa Y, Yoshimura K, Matsui H, et al.. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore). 2021, 100:e25774. 10.1097\/MD.0000000000025774","journal-title":"Medicine (Baltimore)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2022.02.010","article-title":"Delayed hemorrhagic gastritis caused by immunotherapy in a patient with metastatic melanoma","volume":"364","author":"Elmasry M","year":"2022","unstructured":"Elmasry M, Dong B, Rios C, Breaux A, Miller D. Delayed hemorrhagic gastritis caused by immunotherapy in a patient with metastatic melanoma. Am J Med Sci. 2022, 364:343-6. 10.1016\/j.amjms.2022.02.010","journal-title":"Am J Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1055\/a-1899-8619","article-title":"Clinical response in the haustra-like folds observed during peroral cholangioscopy following steroid therapy for immune checkpoint inhibitor-induced cholangitis","volume":"54","author":"Takeda Y","year":"2022","unstructured":"Takeda Y, Inatomi O, Shintani S, Fujimoto T, Nishida A, Kutsumi H, Andoh A. Clinical response in the haustra-like folds observed during peroral cholangioscopy following steroid therapy for immune checkpoint inhibitor-induced cholangitis. Endoscopy. 2022, 54:E1020-1. 10.1055\/a-1899-8619","journal-title":"Endoscopy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/178762-concurrent-nivolumab-induced-gastritis-and-cholangitis-accompanied-by-biliary-tract-hemorrhage-in-a-patient-with-stage-iv-lung-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:13Z","timestamp":1707508753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/178762-concurrent-nivolumab-induced-gastritis-and-cholangitis-accompanied-by-biliary-tract-hemorrhage-in-a-patient-with-stage-iv-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.46392","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,2]]}}}